ArrowMark Colorado Holdings LLC
Position in CLDX — Celldex Therapeutics, Inc.
CIK 1483859
Denver, CO
Position in CLDX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$793,000
+$114,000 QoQ
Shares Held
25,000
0.0% QoQ
Ownership
0.032%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CLDX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ArrowMark Colorado Holdings LLC holds $294,624,620 across 32 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABCL |
AbCellera Biologics Inc.
|
4,105,095 | $32,224,995 | |
| 2 | DFTX |
Definium Therapeutics, Inc.
|
564,069 | $26,533,805 | |
| 3 | MAZE |
Maze Therapeutics, Inc.
|
767,383 | $22,898,708 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
708,385 | $22,144,115 | |
| 5 | RPRX |
Royalty Pharma plc
|
366,199 | $20,532,777 | |
| 6 | PRAX |
Praxis Precision Medicines, Inc.
|
46,030 | $15,410,383 | |
| 7 | ZBIO |
Zenas BioPharma, Inc.
|
573,318 | $14,550,810 | |
| 8 | CGON |
CG Oncology, Inc.
|
155,354 | $11,037,901 |
All Filings in CLDX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $793,000 | 25,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $679,000 | 25,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $646,750 | 25,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $508,750 | 25,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $453,750 | 25,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $631,750 | 25,000 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $849,750 | 25,000 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $925,250 | 25,000 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $1,049,250 | 25,000 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||